TriSalus Reports Mixed Q1 2026: Revenue Dips Amid Commercial Expansion
Event summary
- Q1 2026 revenue from TriNav system was $8.9M, down 2.9% YoY due to commercial expansion.
- Gross margins improved to 86.2% from 83.7% YoY, driven by lower average cost per TriNav unit.
- Operating losses widened to $8.4M from $7.3M YoY, primarily due to higher sales and marketing expenses.
- Net income turned positive at $1.5M, compared to a net loss of $11.1M YoY, boosted by non-cash gains.
- Company raised $46M in gross proceeds from an equity offering, strengthening its balance sheet.
The big picture
TriSalus is positioning itself as a leader in oncology drug delivery technology, integrating its PEDD platform with standard-of-care therapies. The company's strategic focus on commercial expansion and clinical evidence aims to drive long-term growth, despite near-term revenue challenges. The recent equity offering provides a strong financial foundation, but the delayed FDA clearance for TriNav Advance introduces regulatory uncertainty.
What we're watching
- Commercial Expansion
- How the company's commercial expansion will impact its revenue growth and market penetration.
- Regulatory Timing
- Whether the delayed FDA clearance for TriNav Advance will affect the company's long-term growth strategy.
- Clinical Evidence
- The pace at which new clinical evidence supporting PEDD technology will drive adoption across multiple indications.
Related topics